Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Особенности пациентов с ишемической болезнью сердца и сахарным диабетом 2-го типа, подвергающихся плановому чрескожному коронарному вмешательству
Особенности пациентов с ишемической болезнью сердца и сахарным диабетом 2-го типа, подвергающихся плановому чрескожному коронарному вмешательству
Неешпапа А.Г., Каретникова В.Н. Особенности пациентов с ишемической болезнью сердца и сахарным диабетом 2-го типа, подвергающихся плановому чрескожному коронарному вмешательству // CardioСоматика. 2025. Т. 16, № 2. С. 115–126. DOI: 10.17816/CS676532 EDN: IVCKLX
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Обоснование. Пациенты с ишемической болезнью сердца (ИБС) и сахарным диабетом 2-го типа (СД 2) представляют собой особую группу высокого сердечно-сосудистого риска. Получение актуальных данных об их ведении в реальной клинической практике может акцентировать внимание на выявленных пробелах.
Цель. Охарактеризовать клинический профиль, соответствующий пациентам с ИБС и СД 2, определить ассоциации факторов риска (ФР), оценить полноценность принимаемой лекарственной терапии.
Материалы и методы. В исследование включены 50 человек, проходивших плановое госпитальное лечение с целью проведения чрескожного коронарного вмешательства (ЧКВ). У пациентов оценивали половозрастная и клинико-анамнестическая характеристики, антропометрические данные. Из лабораторных показателей определяли уровень общего холестерина, креатинина, глюкозы и гликированного гемоглобина, из инструментальных — фракцию выброса левого желудочка по данным эхокардиографии и объём поражения коронарных артерий по данным коронароангиографии. На основании полученных данных сформирован портрет пациента и отмечена динамика полноценности принимаемой терапии в сравнении с 2022 г. в г. Кемерово.
Результаты. Медикаментозная терапия на момент госпитализации оптимальна не во всех случаях: часть пациентов не принимали входящие в стандартный протокол лечения группы препаратов, в исследуемой группе отмечен недостаточный контроль ключевых ФР сердечно-сосудистых заболеваний (как и в предыдущем исследовании), достижение целевых уровней общего холестерина выявлено только у 30 (60%) человек, целевой уровень гликированного гемоглобина достигнут лишь у 26%, активно курили 48% пациентов, ожирение наблюдалось у 68%.
Заключение. Подготовка пациентов с сочетанием ИБС и СД 2 к плановому ЧКВ включает комплексный подход к управлению факторами риска. Больные СД 2, поступающие на плановое ЧКВ, не всегда имеют оптимальную медикаментозную терапию и должный контроль модифицируемых факторов риска, что требует особого внимания и своевременной коррекции.
Ключевые слова: ишемическая болезнь сердца, плановое чрескожное коронарное вмешательство, сахарный диабет, атеросклероз
AIM: The work aimed to characterize the clinical profile of patients with CAD and T2DM, examine associations with cardiovascular risk factors, and evaluate the adequacy of pharmacotherapy.
METHODS: This study included 50 patients who were electively hospitalized for percutaneous coronary intervention (PCI). Sex, age, and clinical history were recorded, along with anthropometric data. Laboratory parameters included total cholesterol, serum creatinine, blood glucose, and glycated hemoglobin levels. Instrumental assessments included left ventricular ejection fraction by echocardiography and the extent of coronary artery lesions by coronary angiography. Based on these data, a patient profile was constructed, and the adequacy of ongoing pharmacotherapy was evaluated by comparison with data from 2022 in Kemerovo.
RESULTS: Pharmacologic therapy at the time of hospitalization was not optimal in all cases: some patients were not receiving drug classes recommended in standard treatment protocols, and inadequate control of key cardiovascular risk factors was observed (as in the previous study). Target levels of total cholesterol were achieved in only 30 patients (60%), and target levels of glycated hemoglobin in only 26%. Active smoking was reported in 48% of patients, and obesity was observed in 68%.
CONCLUSION: Preparing patients with both CAD and T2DM for elective PCI requires a comprehensive approach to risk factor management. Patients with T2DM undergoing elective PCI often do not receive optimal pharmacologic therapy or achieve adequate control of modifiable risk factors, which warrants close attention and timely correction.
Keywords: coronary artery disease, percutaneous coronary intervention, diabetes mellitus, atherosclerosis
Цель. Охарактеризовать клинический профиль, соответствующий пациентам с ИБС и СД 2, определить ассоциации факторов риска (ФР), оценить полноценность принимаемой лекарственной терапии.
Материалы и методы. В исследование включены 50 человек, проходивших плановое госпитальное лечение с целью проведения чрескожного коронарного вмешательства (ЧКВ). У пациентов оценивали половозрастная и клинико-анамнестическая характеристики, антропометрические данные. Из лабораторных показателей определяли уровень общего холестерина, креатинина, глюкозы и гликированного гемоглобина, из инструментальных — фракцию выброса левого желудочка по данным эхокардиографии и объём поражения коронарных артерий по данным коронароангиографии. На основании полученных данных сформирован портрет пациента и отмечена динамика полноценности принимаемой терапии в сравнении с 2022 г. в г. Кемерово.
Результаты. Медикаментозная терапия на момент госпитализации оптимальна не во всех случаях: часть пациентов не принимали входящие в стандартный протокол лечения группы препаратов, в исследуемой группе отмечен недостаточный контроль ключевых ФР сердечно-сосудистых заболеваний (как и в предыдущем исследовании), достижение целевых уровней общего холестерина выявлено только у 30 (60%) человек, целевой уровень гликированного гемоглобина достигнут лишь у 26%, активно курили 48% пациентов, ожирение наблюдалось у 68%.
Заключение. Подготовка пациентов с сочетанием ИБС и СД 2 к плановому ЧКВ включает комплексный подход к управлению факторами риска. Больные СД 2, поступающие на плановое ЧКВ, не всегда имеют оптимальную медикаментозную терапию и должный контроль модифицируемых факторов риска, что требует особого внимания и своевременной коррекции.
Ключевые слова: ишемическая болезнь сердца, плановое чрескожное коронарное вмешательство, сахарный диабет, атеросклероз
________________________________________________
AIM: The work aimed to characterize the clinical profile of patients with CAD and T2DM, examine associations with cardiovascular risk factors, and evaluate the adequacy of pharmacotherapy.
METHODS: This study included 50 patients who were electively hospitalized for percutaneous coronary intervention (PCI). Sex, age, and clinical history were recorded, along with anthropometric data. Laboratory parameters included total cholesterol, serum creatinine, blood glucose, and glycated hemoglobin levels. Instrumental assessments included left ventricular ejection fraction by echocardiography and the extent of coronary artery lesions by coronary angiography. Based on these data, a patient profile was constructed, and the adequacy of ongoing pharmacotherapy was evaluated by comparison with data from 2022 in Kemerovo.
RESULTS: Pharmacologic therapy at the time of hospitalization was not optimal in all cases: some patients were not receiving drug classes recommended in standard treatment protocols, and inadequate control of key cardiovascular risk factors was observed (as in the previous study). Target levels of total cholesterol were achieved in only 30 patients (60%), and target levels of glycated hemoglobin in only 26%. Active smoking was reported in 48% of patients, and obesity was observed in 68%.
CONCLUSION: Preparing patients with both CAD and T2DM for elective PCI requires a comprehensive approach to risk factor management. Patients with T2DM undergoing elective PCI often do not receive optimal pharmacologic therapy or achieve adequate control of modifiable risk factors, which warrants close attention and timely correction.
Keywords: coronary artery disease, percutaneous coronary intervention, diabetes mellitus, atherosclerosis
Полный текст
Список литературы
1. Yan W, Hua Y. Trends in deaths and disability-adjusted life‑years of ischemic heart disease attributable to high body-mass index worldwide, 1990–2019. BMC Cardiovasc Disord. 2024;482:2024. doi: 10.1186/s12872-024-04136-y EDN: LTEZRC
2. Guduguntla V, Redberg RF. Popular procedures without evidence of benefit: A case study of percutaneous coronary intervention for stable coronary artery disease. Eur J Intern Med. 2021;94:15–21. doi: 10.1016/j.ejim.2021.08.027 EDN: YYPSFL
3. Adil M, Khan I, Hassan Z, et al. One Year Outcomes After Percutaneous Coronary Intervention in Diabetics With Stable Ischemic Heart Disease: A Single-Center Comparative Study. Cureus. 2021;13(1):e12731. doi: 10.7759/cureus.12731 EDN: MIPJHF
4. Verreault-Julien L, Bhatt DL, Jung RG, et al. Predictors of angina resolution after percutaneous coronary intervention in stable coronary artery disease. Coron Artery Dis. 2022;33(2):98–104. doi: 10.1097/MCA.0000000000001081 EDN: AUXIQM
5. Lai CC, Chang BC, Hwang LC. Presence of coronary artery disease in adults with newly detected diabetes mellitus. BMC Cardiovasc Disord. 2025;25(1):76. doi: 10.1186/s12872-024-04463-0 EDN: MIRQZM
6. Grishaev SL, Cherkashin DV, Salukhov VV, Alanichev AE. Modern strategies for the treatment of type 2 diabetes in patients with stable coronary artery disease. Old goals, new opportunities (literature review). Russ J Cardiol. 2024;29(2):5689. doi: 10.15829/1560-4071-2024-5689 EDN: NGLELH
7. Raghavan S, Vassy JL, Ho YL, et al. Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc. 2019;8(4):e011295. doi: 10.1161/JAHA.118.011295
8. Nekrasov AA, Timoshchenko ES, Nekrasova TA, Bakhrak EV. Prognosis of patients with coronary artery disease and diabetes — what to look for. Russian Journal of Cardiology. 2024;29(9):6030. doi: 10.15829/1560-4071-2024-6030 EDN: DPDOQP
9. Fauchier L, Halle M, Herrington WG, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–4140. doi: 10.1093/eurheartj/ehad192
10. Popyhova EB, Stepanova TV, Lagutina DD, et al. The role of diabetes in the onset and development of endothelial dysfunction. Problems of Endocrinology. 2020;66(1):47–55. DOI: 10.14341/probl12212 EDN: BDUNEQ
11. Zhang Y, Song H, Bai J, et al. Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states. Cardiovasc Diabetol. 2023;8;22(1):29. doi: 10.1186/s12933-023-01759-x EDN: ETILXF
12. World Health Organization. Fact sheets. Obesity and Overweight. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed: 16.02.2025.
13. Adhikary D, Barman S, Ranjan R, Stone H. A Systematic Review of Major Cardiovascular Risk Factors: A Growing Global Health Concern. Cureus. 2022;14(10):e30119. doi: 10.7759/cureus.30119 EDN: BSRQNN
14. Kochergina AM, Khorlampenko AA, Karetnikova VN, Barbarash OL. Preparation of patients with type 2 diabetes mellitus for elective percutaneous coronary intervention. Fundamental and Clinical Medicine. 2023;8(3):44–52. doi: 10.23946/2500-0764-2023-8-3-44-52 EDN: OYQFHG
15. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm — 2023 Update. Endocr Pract. 2023;29(5):305–340. doi: 10.1016/j.eprac.2023.02.001 EDN: KSPDHV
16. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists. American College of Endocrinology Comprehensive Diabetes Management Algorithm. Endocrine Practice. 2017;23(4): 573–596. doi: 10.4158/EP171219.APP EDN: PKJOQP
17. Tan JK, Lim GH, Mohamed Salim NN, et al. Associations Between Mean HbA1c, HbA1c Variability, and Both Mortality and Macrovascular Complications in Patients with Diabetes Mellitus: A Registry-Based Cohort Study. Clinical Epidemiology. 2023;15:137–149. doi: 10.2147/CLEP.S391749 EDN: RXECBZ
18. Karetnikova VN, Kchorlampenko AA, Osokina AV, et al. Role of glycemic control in elective percutaneous coronary interventions in patients with type 2 diabetes. Russ J Cardiol. 2022;27(12):5137. doi: 10.15829/1560-4071-2022-5137 EDN: OXSWNA
19. Critchley JA, Carey IM, Harris T, et al. Variability in Glycated Hemoglobin and risk of poor outcomes among people with type 2 diabetes in a large primary care Cohort Study. Diabetes Care. 2019;42(12):2237–2246. doi:10.2337/dc19-0848
20. Lin W. The Association between Body Mass Index and Glycohemoglobin (HbA1c) in the US Population’s Diabetes Status. Int J Environ Res Public Health. 2024;21(5):517. doi: 10.3390/ijerph21050517 EDN: JHJVJC
21. Kennedy-Martin T, Boye KS, Kennedy-Martin M. The Association Between Body Mass Index and Glycemic Control in Patients with Type 2 Diabetes Across Eight Countries: A Literature Review. Curr Res Diabetes Obes J. 2021;15(1):555904. doi: 10.19080/CRDOJ.2021.15.555904 EDN: DJGUOQ
22. Thapa S, Vaidya N, Pandey R, Takanche JSh. Association of Non High Density Lipoprotein-Cholesterol and HbA1c in Type 2 Diabetes Mellitus. Journal of Nobel Medical College. 2023;12(2):30–35. doi: 10.3126/jonmc.v12i2.61111 EDN: FGFGMY
23. Wahab Z. Correlation between Glycosylated Haemoglobin and Dyslipidaemia in Patients with Type 2 Diabetes Mellitus. IAR Journal of Medicine and Surgery Research. 2021;2(5):10–13. doi: 10.47310/iarjmsr.2021.V02i05.02 EDN: AKNGTD
24. Samorodskaya IV, Bubnova MG, Akulova OA, et al. Male and female mortality rates due to acute types of coronary artery disease in five-year age groups in the Russian Federation: what do the numbers mean? Cardiovascular Therapy and Prevention. 2022;21(12):3460. doi: 10.15829/1728-8800-2022-3460 EDN: MNZDMQ
25. Gao Z, Xu B, Kirtane AJ, et al. Impact of depressed left ventricular function on outcomes in patients with three-vessel coronary disease undergoing percutaneous coronary intervention. Chin Med J (Engl). 2013;126(4):609–614. doi: 10.3760/cma.j.issn.0366-6999.20121583
26. Teplyakov AT, Grakova EV, Svarovskaya AV, et al. Efficacy of endovascular coronary revascularization in patient with chd with reduced left ventricular. Complex Issues of Cardiovascular Diseases. 2017;(1):79–91. doi: 10.17802/2306-1278-2017-1-79-91 EDN: YLEIJX
27. Savage P, Watson C, Coburn J, et al. Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta-analysis. ESC Heart Fail. 2024;11(6):3636–3648. doi: 10.1002/ehf2.14993 EDN: OWSFJE
28. Suman S, Pravalika J, Manjula P, Farooq U. Gender and CVD- Does It Really Matters? Curr Probl Cardiol. 2023;48(5):101604. doi: 10.1016/j.cpcardiol.2023.101604 EDN: MKXPON
29. Shalnova SA, Drapkina OM, Kutsenko VA, et al. Chernykh on behalf of the ESSE-RF study participants. T.M. Myocardial infarction in the population of some Russian regions and its prognostic value. Russian Journal of Cardiology. 2022;27(6):4952. doi: 10.15829/1560-4071-2022-4952
30. Niemann B, Rohrbach S, Miller MR, et al. Oxidative Stress and Cardiovascular Risk: Obesity, Diabetes, Smoking, and Pollution: Part 3 of a 3-Part Series. J Am Coll Cardiol. 2017;70(2):230–251. doi: 10.1016/j.jacc.2017.05.043
31. Campagna D, Alamo A, Di Pino A, et al. Smoking and diabetes: dangerous liaisons and confusing relationships. Diabetol Metab Syndr. 2023;15(1):117. doi: 10.1186/s13098-023-01099-6 EDN: JGILXA
32. Niket V. A Study of HbA1c, fasting and 2 hour plasma glucose levels in current smokers presenting at a tertiary care hospital in North India. Int J Adv Med. 2018;5:38–46. doi: 10.18203/2349-3933.ijam20180002
33. Riaz F, Al Shaikh A, Anjum Q, et al. Factors related to the uncontrolled fasting blood sugar among type 2 diabetic patients attending primary health care center, Abha city, Saudi Arabia. Int J Clin Pract. 2021;75(7):e14168. doi: 10.1111/ijcp.14168 EDN: FXSXXV
34. Yang Y, Peng N, Chen G, et al. Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events. Cardiovasc Diabetol. 2022;21(1):14. doi: 10.1186/s12933-022-01447-2 EDN: LZLHGG
35. Mironchuk NN, Kochegura TN. Analysis of the main indicators of secondary prevention in patients with coronary heart disease. University Therapeutic Journal. 2024;6(2):97–106. doi: 10.56871/UTJ.2024.42.39.011 EDN: TSYFAY
2. Guduguntla V, Redberg RF. Popular procedures without evidence of benefit: A case study of percutaneous coronary intervention for stable coronary artery disease. Eur J Intern Med. 2021;94:15–21. doi: 10.1016/j.ejim.2021.08.027 EDN: YYPSFL
3. Adil M, Khan I, Hassan Z, et al. One Year Outcomes After Percutaneous Coronary Intervention in Diabetics With Stable Ischemic Heart Disease: A Single-Center Comparative Study. Cureus. 2021;13(1):e12731. doi: 10.7759/cureus.12731 EDN: MIPJHF
4. Verreault-Julien L, Bhatt DL, Jung RG, et al. Predictors of angina resolution after percutaneous coronary intervention in stable coronary artery disease. Coron Artery Dis. 2022;33(2):98–104. doi: 10.1097/MCA.0000000000001081 EDN: AUXIQM
5. Lai CC, Chang BC, Hwang LC. Presence of coronary artery disease in adults with newly detected diabetes mellitus. BMC Cardiovasc Disord. 2025;25(1):76. doi: 10.1186/s12872-024-04463-0 EDN: MIRQZM
6. Grishaev SL, Cherkashin DV, Salukhov VV, Alanichev AE. Modern strategies for the treatment of type 2 diabetes in patients with stable coronary artery disease. Old goals, new opportunities (literature review). Russ J Cardiol. 2024;29(2):5689. doi: 10.15829/1560-4071-2024-5689 EDN: NGLELH
7. Raghavan S, Vassy JL, Ho YL, et al. Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc. 2019;8(4):e011295. doi: 10.1161/JAHA.118.011295
8. Nekrasov AA, Timoshchenko ES, Nekrasova TA, Bakhrak EV. Prognosis of patients with coronary artery disease and diabetes — what to look for. Russian Journal of Cardiology. 2024;29(9):6030. doi: 10.15829/1560-4071-2024-6030 EDN: DPDOQP
9. Fauchier L, Halle M, Herrington WG, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–4140. doi: 10.1093/eurheartj/ehad192
10. Popyhova EB, Stepanova TV, Lagutina DD, et al. The role of diabetes in the onset and development of endothelial dysfunction. Problems of Endocrinology. 2020;66(1):47–55. DOI: 10.14341/probl12212 EDN: BDUNEQ
11. Zhang Y, Song H, Bai J, et al. Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states. Cardiovasc Diabetol. 2023;8;22(1):29. doi: 10.1186/s12933-023-01759-x EDN: ETILXF
12. World Health Organization. Fact sheets. Obesity and Overweight. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed: 16.02.2025.
13. Adhikary D, Barman S, Ranjan R, Stone H. A Systematic Review of Major Cardiovascular Risk Factors: A Growing Global Health Concern. Cureus. 2022;14(10):e30119. doi: 10.7759/cureus.30119 EDN: BSRQNN
14. Kochergina AM, Khorlampenko AA, Karetnikova VN, Barbarash OL. Preparation of patients with type 2 diabetes mellitus for elective percutaneous coronary intervention. Fundamental and Clinical Medicine. 2023;8(3):44–52. doi: 10.23946/2500-0764-2023-8-3-44-52 EDN: OYQFHG
15. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm — 2023 Update. Endocr Pract. 2023;29(5):305–340. doi: 10.1016/j.eprac.2023.02.001 EDN: KSPDHV
16. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists. American College of Endocrinology Comprehensive Diabetes Management Algorithm. Endocrine Practice. 2017;23(4): 573–596. doi: 10.4158/EP171219.APP EDN: PKJOQP
17. Tan JK, Lim GH, Mohamed Salim NN, et al. Associations Between Mean HbA1c, HbA1c Variability, and Both Mortality and Macrovascular Complications in Patients with Diabetes Mellitus: A Registry-Based Cohort Study. Clinical Epidemiology. 2023;15:137–149. doi: 10.2147/CLEP.S391749 EDN: RXECBZ
18. Karetnikova VN, Kchorlampenko AA, Osokina AV, et al. Role of glycemic control in elective percutaneous coronary interventions in patients with type 2 diabetes. Russ J Cardiol. 2022;27(12):5137. doi: 10.15829/1560-4071-2022-5137 EDN: OXSWNA
19. Critchley JA, Carey IM, Harris T, et al. Variability in Glycated Hemoglobin and risk of poor outcomes among people with type 2 diabetes in a large primary care Cohort Study. Diabetes Care. 2019;42(12):2237–2246. doi:10.2337/dc19-0848
20. Lin W. The Association between Body Mass Index and Glycohemoglobin (HbA1c) in the US Population’s Diabetes Status. Int J Environ Res Public Health. 2024;21(5):517. doi: 10.3390/ijerph21050517 EDN: JHJVJC
21. Kennedy-Martin T, Boye KS, Kennedy-Martin M. The Association Between Body Mass Index and Glycemic Control in Patients with Type 2 Diabetes Across Eight Countries: A Literature Review. Curr Res Diabetes Obes J. 2021;15(1):555904. doi: 10.19080/CRDOJ.2021.15.555904 EDN: DJGUOQ
22. Thapa S, Vaidya N, Pandey R, Takanche JSh. Association of Non High Density Lipoprotein-Cholesterol and HbA1c in Type 2 Diabetes Mellitus. Journal of Nobel Medical College. 2023;12(2):30–35. doi: 10.3126/jonmc.v12i2.61111 EDN: FGFGMY
23. Wahab Z. Correlation between Glycosylated Haemoglobin and Dyslipidaemia in Patients with Type 2 Diabetes Mellitus. IAR Journal of Medicine and Surgery Research. 2021;2(5):10–13. doi: 10.47310/iarjmsr.2021.V02i05.02 EDN: AKNGTD
24. Samorodskaya IV, Bubnova MG, Akulova OA, et al. Male and female mortality rates due to acute types of coronary artery disease in five-year age groups in the Russian Federation: what do the numbers mean? Cardiovascular Therapy and Prevention. 2022;21(12):3460. doi: 10.15829/1728-8800-2022-3460 EDN: MNZDMQ
25. Gao Z, Xu B, Kirtane AJ, et al. Impact of depressed left ventricular function on outcomes in patients with three-vessel coronary disease undergoing percutaneous coronary intervention. Chin Med J (Engl). 2013;126(4):609–614. doi: 10.3760/cma.j.issn.0366-6999.20121583
26. Teplyakov AT, Grakova EV, Svarovskaya AV, et al. Efficacy of endovascular coronary revascularization in patient with chd with reduced left ventricular. Complex Issues of Cardiovascular Diseases. 2017;(1):79–91. doi: 10.17802/2306-1278-2017-1-79-91 EDN: YLEIJX
27. Savage P, Watson C, Coburn J, et al. Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta-analysis. ESC Heart Fail. 2024;11(6):3636–3648. doi: 10.1002/ehf2.14993 EDN: OWSFJE
28. Suman S, Pravalika J, Manjula P, Farooq U. Gender and CVD- Does It Really Matters? Curr Probl Cardiol. 2023;48(5):101604. doi: 10.1016/j.cpcardiol.2023.101604 EDN: MKXPON
29. Shalnova SA, Drapkina OM, Kutsenko VA, et al. Chernykh on behalf of the ESSE-RF study participants. T.M. Myocardial infarction in the population of some Russian regions and its prognostic value. Russian Journal of Cardiology. 2022;27(6):4952. doi: 10.15829/1560-4071-2022-4952
30. Niemann B, Rohrbach S, Miller MR, et al. Oxidative Stress and Cardiovascular Risk: Obesity, Diabetes, Smoking, and Pollution: Part 3 of a 3-Part Series. J Am Coll Cardiol. 2017;70(2):230–251. doi: 10.1016/j.jacc.2017.05.043
31. Campagna D, Alamo A, Di Pino A, et al. Smoking and diabetes: dangerous liaisons and confusing relationships. Diabetol Metab Syndr. 2023;15(1):117. doi: 10.1186/s13098-023-01099-6 EDN: JGILXA
32. Niket V. A Study of HbA1c, fasting and 2 hour plasma glucose levels in current smokers presenting at a tertiary care hospital in North India. Int J Adv Med. 2018;5:38–46. doi: 10.18203/2349-3933.ijam20180002
33. Riaz F, Al Shaikh A, Anjum Q, et al. Factors related to the uncontrolled fasting blood sugar among type 2 diabetic patients attending primary health care center, Abha city, Saudi Arabia. Int J Clin Pract. 2021;75(7):e14168. doi: 10.1111/ijcp.14168 EDN: FXSXXV
34. Yang Y, Peng N, Chen G, et al. Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events. Cardiovasc Diabetol. 2022;21(1):14. doi: 10.1186/s12933-022-01447-2 EDN: LZLHGG
35. Mironchuk NN, Kochegura TN. Analysis of the main indicators of secondary prevention in patients with coronary heart disease. University Therapeutic Journal. 2024;6(2):97–106. doi: 10.56871/UTJ.2024.42.39.011 EDN: TSYFAY
2. Guduguntla V, Redberg RF. Popular procedures without evidence of benefit: A case study of percutaneous coronary intervention for stable coronary artery disease. Eur J Intern Med. 2021;94:15–21. doi: 10.1016/j.ejim.2021.08.027 EDN: YYPSFL
3. Adil M, Khan I, Hassan Z, et al. One Year Outcomes After Percutaneous Coronary Intervention in Diabetics With Stable Ischemic Heart Disease: A Single-Center Comparative Study. Cureus. 2021;13(1):e12731. doi: 10.7759/cureus.12731 EDN: MIPJHF
4. Verreault-Julien L, Bhatt DL, Jung RG, et al. Predictors of angina resolution after percutaneous coronary intervention in stable coronary artery disease. Coron Artery Dis. 2022;33(2):98–104. doi: 10.1097/MCA.0000000000001081 EDN: AUXIQM
5. Lai CC, Chang BC, Hwang LC. Presence of coronary artery disease in adults with newly detected diabetes mellitus. BMC Cardiovasc Disord. 2025;25(1):76. doi: 10.1186/s12872-024-04463-0 EDN: MIRQZM
6. Grishaev SL, Cherkashin DV, Salukhov VV, Alanichev AE. Modern strategies for the treatment of type 2 diabetes in patients with stable coronary artery disease. Old goals, new opportunities (literature review). Russ J Cardiol. 2024;29(2):5689. doi: 10.15829/1560-4071-2024-5689 EDN: NGLELH
7. Raghavan S, Vassy JL, Ho YL, et al. Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc. 2019;8(4):e011295. doi: 10.1161/JAHA.118.011295
8. Nekrasov AA, Timoshchenko ES, Nekrasova TA, Bakhrak EV. Prognosis of patients with coronary artery disease and diabetes — what to look for. Russian Journal of Cardiology. 2024;29(9):6030. doi: 10.15829/1560-4071-2024-6030 EDN: DPDOQP
9. Fauchier L, Halle M, Herrington WG, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–4140. doi: 10.1093/eurheartj/ehad192
10. Popyhova EB, Stepanova TV, Lagutina DD, et al. The role of diabetes in the onset and development of endothelial dysfunction. Problems of Endocrinology. 2020;66(1):47–55. DOI: 10.14341/probl12212 EDN: BDUNEQ
11. Zhang Y, Song H, Bai J, et al. Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states. Cardiovasc Diabetol. 2023;8;22(1):29. doi: 10.1186/s12933-023-01759-x EDN: ETILXF
12. World Health Organization. Fact sheets. Obesity and Overweight. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed: 16.02.2025.
13. Adhikary D, Barman S, Ranjan R, Stone H. A Systematic Review of Major Cardiovascular Risk Factors: A Growing Global Health Concern. Cureus. 2022;14(10):e30119. doi: 10.7759/cureus.30119 EDN: BSRQNN
14. Kochergina AM, Khorlampenko AA, Karetnikova VN, Barbarash OL. Preparation of patients with type 2 diabetes mellitus for elective percutaneous coronary intervention. Fundamental and Clinical Medicine. 2023;8(3):44–52. doi: 10.23946/2500-0764-2023-8-3-44-52 EDN: OYQFHG
15. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm — 2023 Update. Endocr Pract. 2023;29(5):305–340. doi: 10.1016/j.eprac.2023.02.001 EDN: KSPDHV
16. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists. American College of Endocrinology Comprehensive Diabetes Management Algorithm. Endocrine Practice. 2017;23(4): 573–596. doi: 10.4158/EP171219.APP EDN: PKJOQP
17. Tan JK, Lim GH, Mohamed Salim NN, et al. Associations Between Mean HbA1c, HbA1c Variability, and Both Mortality and Macrovascular Complications in Patients with Diabetes Mellitus: A Registry-Based Cohort Study. Clinical Epidemiology. 2023;15:137–149. doi: 10.2147/CLEP.S391749 EDN: RXECBZ
18. Karetnikova VN, Kchorlampenko AA, Osokina AV, et al. Role of glycemic control in elective percutaneous coronary interventions in patients with type 2 diabetes. Russ J Cardiol. 2022;27(12):5137. doi: 10.15829/1560-4071-2022-5137 EDN: OXSWNA
19. Critchley JA, Carey IM, Harris T, et al. Variability in Glycated Hemoglobin and risk of poor outcomes among people with type 2 diabetes in a large primary care Cohort Study. Diabetes Care. 2019;42(12):2237–2246. doi:10.2337/dc19-0848
20. Lin W. The Association between Body Mass Index and Glycohemoglobin (HbA1c) in the US Population’s Diabetes Status. Int J Environ Res Public Health. 2024;21(5):517. doi: 10.3390/ijerph21050517 EDN: JHJVJC
21. Kennedy-Martin T, Boye KS, Kennedy-Martin M. The Association Between Body Mass Index and Glycemic Control in Patients with Type 2 Diabetes Across Eight Countries: A Literature Review. Curr Res Diabetes Obes J. 2021;15(1):555904. doi: 10.19080/CRDOJ.2021.15.555904 EDN: DJGUOQ
22. Thapa S, Vaidya N, Pandey R, Takanche JSh. Association of Non High Density Lipoprotein-Cholesterol and HbA1c in Type 2 Diabetes Mellitus. Journal of Nobel Medical College. 2023;12(2):30–35. doi: 10.3126/jonmc.v12i2.61111 EDN: FGFGMY
23. Wahab Z. Correlation between Glycosylated Haemoglobin and Dyslipidaemia in Patients with Type 2 Diabetes Mellitus. IAR Journal of Medicine and Surgery Research. 2021;2(5):10–13. doi: 10.47310/iarjmsr.2021.V02i05.02 EDN: AKNGTD
24. Samorodskaya IV, Bubnova MG, Akulova OA, et al. Male and female mortality rates due to acute types of coronary artery disease in five-year age groups in the Russian Federation: what do the numbers mean? Cardiovascular Therapy and Prevention. 2022;21(12):3460. doi: 10.15829/1728-8800-2022-3460 EDN: MNZDMQ
25. Gao Z, Xu B, Kirtane AJ, et al. Impact of depressed left ventricular function on outcomes in patients with three-vessel coronary disease undergoing percutaneous coronary intervention. Chin Med J (Engl). 2013;126(4):609–614. doi: 10.3760/cma.j.issn.0366-6999.20121583
26. Teplyakov AT, Grakova EV, Svarovskaya AV, et al. Efficacy of endovascular coronary revascularization in patient with chd with reduced left ventricular. Complex Issues of Cardiovascular Diseases. 2017;(1):79–91. doi: 10.17802/2306-1278-2017-1-79-91 EDN: YLEIJX
27. Savage P, Watson C, Coburn J, et al. Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta-analysis. ESC Heart Fail. 2024;11(6):3636–3648. doi: 10.1002/ehf2.14993 EDN: OWSFJE
28. Suman S, Pravalika J, Manjula P, Farooq U. Gender and CVD- Does It Really Matters? Curr Probl Cardiol. 2023;48(5):101604. doi: 10.1016/j.cpcardiol.2023.101604 EDN: MKXPON
29. Shalnova SA, Drapkina OM, Kutsenko VA, et al. Chernykh on behalf of the ESSE-RF study participants. T.M. Myocardial infarction in the population of some Russian regions and its prognostic value. Russian Journal of Cardiology. 2022;27(6):4952. doi: 10.15829/1560-4071-2022-4952
30. Niemann B, Rohrbach S, Miller MR, et al. Oxidative Stress and Cardiovascular Risk: Obesity, Diabetes, Smoking, and Pollution: Part 3 of a 3-Part Series. J Am Coll Cardiol. 2017;70(2):230–251. doi: 10.1016/j.jacc.2017.05.043
31. Campagna D, Alamo A, Di Pino A, et al. Smoking and diabetes: dangerous liaisons and confusing relationships. Diabetol Metab Syndr. 2023;15(1):117. doi: 10.1186/s13098-023-01099-6 EDN: JGILXA
32. Niket V. A Study of HbA1c, fasting and 2 hour plasma glucose levels in current smokers presenting at a tertiary care hospital in North India. Int J Adv Med. 2018;5:38–46. doi: 10.18203/2349-3933.ijam20180002
33. Riaz F, Al Shaikh A, Anjum Q, et al. Factors related to the uncontrolled fasting blood sugar among type 2 diabetic patients attending primary health care center, Abha city, Saudi Arabia. Int J Clin Pract. 2021;75(7):e14168. doi: 10.1111/ijcp.14168 EDN: FXSXXV
34. Yang Y, Peng N, Chen G, et al. Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events. Cardiovasc Diabetol. 2022;21(1):14. doi: 10.1186/s12933-022-01447-2 EDN: LZLHGG
35. Mironchuk NN, Kochegura TN. Analysis of the main indicators of secondary prevention in patients with coronary heart disease. University Therapeutic Journal. 2024;6(2):97–106. doi: 10.56871/UTJ.2024.42.39.011 EDN: TSYFAY
________________________________________________
2. Guduguntla V, Redberg RF. Popular procedures without evidence of benefit: A case study of percutaneous coronary intervention for stable coronary artery disease. Eur J Intern Med. 2021;94:15–21. doi: 10.1016/j.ejim.2021.08.027 EDN: YYPSFL
3. Adil M, Khan I, Hassan Z, et al. One Year Outcomes After Percutaneous Coronary Intervention in Diabetics With Stable Ischemic Heart Disease: A Single-Center Comparative Study. Cureus. 2021;13(1):e12731. doi: 10.7759/cureus.12731 EDN: MIPJHF
4. Verreault-Julien L, Bhatt DL, Jung RG, et al. Predictors of angina resolution after percutaneous coronary intervention in stable coronary artery disease. Coron Artery Dis. 2022;33(2):98–104. doi: 10.1097/MCA.0000000000001081 EDN: AUXIQM
5. Lai CC, Chang BC, Hwang LC. Presence of coronary artery disease in adults with newly detected diabetes mellitus. BMC Cardiovasc Disord. 2025;25(1):76. doi: 10.1186/s12872-024-04463-0 EDN: MIRQZM
6. Grishaev SL, Cherkashin DV, Salukhov VV, Alanichev AE. Modern strategies for the treatment of type 2 diabetes in patients with stable coronary artery disease. Old goals, new opportunities (literature review). Russ J Cardiol. 2024;29(2):5689. doi: 10.15829/1560-4071-2024-5689 EDN: NGLELH
7. Raghavan S, Vassy JL, Ho YL, et al. Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc. 2019;8(4):e011295. doi: 10.1161/JAHA.118.011295
8. Nekrasov AA, Timoshchenko ES, Nekrasova TA, Bakhrak EV. Prognosis of patients with coronary artery disease and diabetes — what to look for. Russian Journal of Cardiology. 2024;29(9):6030. doi: 10.15829/1560-4071-2024-6030 EDN: DPDOQP
9. Fauchier L, Halle M, Herrington WG, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–4140. doi: 10.1093/eurheartj/ehad192
10. Popyhova EB, Stepanova TV, Lagutina DD, et al. The role of diabetes in the onset and development of endothelial dysfunction. Problems of Endocrinology. 2020;66(1):47–55. DOI: 10.14341/probl12212 EDN: BDUNEQ
11. Zhang Y, Song H, Bai J, et al. Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states. Cardiovasc Diabetol. 2023;8;22(1):29. doi: 10.1186/s12933-023-01759-x EDN: ETILXF
12. World Health Organization. Fact sheets. Obesity and Overweight. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed: 16.02.2025.
13. Adhikary D, Barman S, Ranjan R, Stone H. A Systematic Review of Major Cardiovascular Risk Factors: A Growing Global Health Concern. Cureus. 2022;14(10):e30119. doi: 10.7759/cureus.30119 EDN: BSRQNN
14. Kochergina AM, Khorlampenko AA, Karetnikova VN, Barbarash OL. Preparation of patients with type 2 diabetes mellitus for elective percutaneous coronary intervention. Fundamental and Clinical Medicine. 2023;8(3):44–52. doi: 10.23946/2500-0764-2023-8-3-44-52 EDN: OYQFHG
15. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm — 2023 Update. Endocr Pract. 2023;29(5):305–340. doi: 10.1016/j.eprac.2023.02.001 EDN: KSPDHV
16. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists. American College of Endocrinology Comprehensive Diabetes Management Algorithm. Endocrine Practice. 2017;23(4): 573–596. doi: 10.4158/EP171219.APP EDN: PKJOQP
17. Tan JK, Lim GH, Mohamed Salim NN, et al. Associations Between Mean HbA1c, HbA1c Variability, and Both Mortality and Macrovascular Complications in Patients with Diabetes Mellitus: A Registry-Based Cohort Study. Clinical Epidemiology. 2023;15:137–149. doi: 10.2147/CLEP.S391749 EDN: RXECBZ
18. Karetnikova VN, Kchorlampenko AA, Osokina AV, et al. Role of glycemic control in elective percutaneous coronary interventions in patients with type 2 diabetes. Russ J Cardiol. 2022;27(12):5137. doi: 10.15829/1560-4071-2022-5137 EDN: OXSWNA
19. Critchley JA, Carey IM, Harris T, et al. Variability in Glycated Hemoglobin and risk of poor outcomes among people with type 2 diabetes in a large primary care Cohort Study. Diabetes Care. 2019;42(12):2237–2246. doi:10.2337/dc19-0848
20. Lin W. The Association between Body Mass Index and Glycohemoglobin (HbA1c) in the US Population’s Diabetes Status. Int J Environ Res Public Health. 2024;21(5):517. doi: 10.3390/ijerph21050517 EDN: JHJVJC
21. Kennedy-Martin T, Boye KS, Kennedy-Martin M. The Association Between Body Mass Index and Glycemic Control in Patients with Type 2 Diabetes Across Eight Countries: A Literature Review. Curr Res Diabetes Obes J. 2021;15(1):555904. doi: 10.19080/CRDOJ.2021.15.555904 EDN: DJGUOQ
22. Thapa S, Vaidya N, Pandey R, Takanche JSh. Association of Non High Density Lipoprotein-Cholesterol and HbA1c in Type 2 Diabetes Mellitus. Journal of Nobel Medical College. 2023;12(2):30–35. doi: 10.3126/jonmc.v12i2.61111 EDN: FGFGMY
23. Wahab Z. Correlation between Glycosylated Haemoglobin and Dyslipidaemia in Patients with Type 2 Diabetes Mellitus. IAR Journal of Medicine and Surgery Research. 2021;2(5):10–13. doi: 10.47310/iarjmsr.2021.V02i05.02 EDN: AKNGTD
24. Samorodskaya IV, Bubnova MG, Akulova OA, et al. Male and female mortality rates due to acute types of coronary artery disease in five-year age groups in the Russian Federation: what do the numbers mean? Cardiovascular Therapy and Prevention. 2022;21(12):3460. doi: 10.15829/1728-8800-2022-3460 EDN: MNZDMQ
25. Gao Z, Xu B, Kirtane AJ, et al. Impact of depressed left ventricular function on outcomes in patients with three-vessel coronary disease undergoing percutaneous coronary intervention. Chin Med J (Engl). 2013;126(4):609–614. doi: 10.3760/cma.j.issn.0366-6999.20121583
26. Teplyakov AT, Grakova EV, Svarovskaya AV, et al. Efficacy of endovascular coronary revascularization in patient with chd with reduced left ventricular. Complex Issues of Cardiovascular Diseases. 2017;(1):79–91. doi: 10.17802/2306-1278-2017-1-79-91 EDN: YLEIJX
27. Savage P, Watson C, Coburn J, et al. Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta-analysis. ESC Heart Fail. 2024;11(6):3636–3648. doi: 10.1002/ehf2.14993 EDN: OWSFJE
28. Suman S, Pravalika J, Manjula P, Farooq U. Gender and CVD- Does It Really Matters? Curr Probl Cardiol. 2023;48(5):101604. doi: 10.1016/j.cpcardiol.2023.101604 EDN: MKXPON
29. Shalnova SA, Drapkina OM, Kutsenko VA, et al. Chernykh on behalf of the ESSE-RF study participants. T.M. Myocardial infarction in the population of some Russian regions and its prognostic value. Russian Journal of Cardiology. 2022;27(6):4952. doi: 10.15829/1560-4071-2022-4952
30. Niemann B, Rohrbach S, Miller MR, et al. Oxidative Stress and Cardiovascular Risk: Obesity, Diabetes, Smoking, and Pollution: Part 3 of a 3-Part Series. J Am Coll Cardiol. 2017;70(2):230–251. doi: 10.1016/j.jacc.2017.05.043
31. Campagna D, Alamo A, Di Pino A, et al. Smoking and diabetes: dangerous liaisons and confusing relationships. Diabetol Metab Syndr. 2023;15(1):117. doi: 10.1186/s13098-023-01099-6 EDN: JGILXA
32. Niket V. A Study of HbA1c, fasting and 2 hour plasma glucose levels in current smokers presenting at a tertiary care hospital in North India. Int J Adv Med. 2018;5:38–46. doi: 10.18203/2349-3933.ijam20180002
33. Riaz F, Al Shaikh A, Anjum Q, et al. Factors related to the uncontrolled fasting blood sugar among type 2 diabetic patients attending primary health care center, Abha city, Saudi Arabia. Int J Clin Pract. 2021;75(7):e14168. doi: 10.1111/ijcp.14168 EDN: FXSXXV
34. Yang Y, Peng N, Chen G, et al. Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events. Cardiovasc Diabetol. 2022;21(1):14. doi: 10.1186/s12933-022-01447-2 EDN: LZLHGG
35. Mironchuk NN, Kochegura TN. Analysis of the main indicators of secondary prevention in patients with coronary heart disease. University Therapeutic Journal. 2024;6(2):97–106. doi: 10.56871/UTJ.2024.42.39.011 EDN: TSYFAY
Авторы
А.Г. Неешпапа*1, В.Н. Каретникова1,2
1Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний, Кемерово, Россия;
2Кемеровский государственный медицинский университет, Кемерово, Россия
*anastasiyaneeshpapa@mail.ru
1Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia;
2Kemerovo State Medical University, Kemerovo, Russia
*anastasiyaneeshpapa@mail.ru
1Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний, Кемерово, Россия;
2Кемеровский государственный медицинский университет, Кемерово, Россия
*anastasiyaneeshpapa@mail.ru
________________________________________________
1Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia;
2Kemerovo State Medical University, Kemerovo, Russia
*anastasiyaneeshpapa@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.